Abstract Library

#2287 Mitochondrial or Aerobic Glycolysis Oriented Metabolism May Define Pancreatic Neuroendocrine Tumors (PanNET) Resistance to mTOR-Targeting Therapies

Introduction: The mTOR inhibitor Everolimus is approved for the treatment of PanNET and no predictive biomarker is available. mTOR is a central node controlling mitochondrial and aerobic glycolytic metabolisms.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Cros J, Bucau M, Raffenne J, Soukeur M, Dumont F,

Keywords: mTOR, everolimus, pancreatic NET, metabolism,

#1412 MiR-196a Is Specifically Regulated in FDG-PET Positive and Negative Small Intestinal Neuroendocrine Tumor Patients at Late Stage of Disease

Introduction: This collaborative research plan aims at elucidating the glycolytic metabolism in advanced FDG-PET positive (+) and FDG-PET negative (-) small intestinal neuroendocrine tumor (SI-NET) patients treated with Lutetium peptide receptor radionuclide therapy (177Lu-PRRT).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Giandomenico V

Authors: Giandomenico V, Li S, Lind T, Boccherini M, Skogseid B,

Keywords: glycolytic metabolism, peptide receptor radionuclide therapy (PRRT), serum samples, miRNA, FDG-PET positive and-PET negative SI-NET patients,